RecruitingNCT07377175Updated Jan 29, 2026

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 After Single/Multiple Doses.

A Phase 1 interventional study of BSY001 for Injection (37.5mg) and BSY001 for Injection (75 mg) in Smallpox, Cowpox and Monkeypox, sponsored by China National Biotec Group Company Limited. Recruiting at 1 site in China. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-29.

Sponsored by China National Biotec Group Company Limited · Phase 1, Interventional, and Treatment

Phase: Phase 1
Study type: Interventional
Enrollment: 76
Allocation: Randomized
Ages: 18 Years to 50 Years
Sex: All

Study summary

A Two-Phase, Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 for Injection Following Single or Multiple Doses in Healthy Subjects

Read the detailed description

This study is divided into two parts: a single-dose study (BSY001-A) and a multiple-dose study (BSY001-B). Subjects for BSY001-B will be enrolled only after all subjects participating in BSY001-A have completed the pharmacokinetic (PK) tests and safety follow-ups for all dose groups, and the corresponding PK parameters and preliminary safety results have been obtained.

BSY001-A: A single ascending dose study conducted in healthy subjects. The trial includes five dose groups: 37.5, 75, 150, 200, and 300 mg, starting from the low-dose group. A total of 46 subjects are planned for enrollment. For the 37.5 mg and 75 mg dose groups, 8 subjects will be enrolled in each group, with 6 receiving BSY001 for injection and 2 receiving placebo. For the 150 mg, 200 mg, and 300 mg dose groups, 10 subjects will be enrolled in each group, including 8 receiving BSY001 for injection and 2 receiving placebo. All subjects will receive a single administration of either BSY001 for injection or placebo. PK blood samples will be collected both prior to and after the initiation of dosing. Subjects who complete PK blood sampling and safety follow-ups may be discontinued from the study. Tolerability assessment will be performed on Day 4 for each dose group, and dosing of the next dose group may commence only after the Safety Monitoring Committee (SMC) confirms safety and tolerability.

BSY001-B: A randomized, double-blind, multiple-dose pharmacokinetic study conducted in healthy subjects. A total of 30 eligible subjects will be enrolled after screening, including 24 in the treatment group and 6 in the placebo group. Subjects will receive 200 mg of BSY001 for injection or placebo, administered once every 12 hours ± 10 minutes for 14 consecutive days. During hospitalization, subjects will be under centralized management by the study center, with blood sample collection and safety assessments performed as scheduled.

Conditions studied

Smallpox
Cowpox
Monkeypox
Poxvirus Infection

Browse trials for

Who can participate

Ages eligible: 18 Years to 50 Years
Sexes eligible: All
Accepts healthy volunteers: Yes

Inclusion criteria

Subjects voluntarily participate in the study, sign the informed consent form, and agree to comply with all study requirements;
Aged ≥ 18 years and ≤ 50 years (based on the date of signing the informed consent form), including both males and females;
Body Mass Index (BMI) between 19.0 and 30.0 kg/m² (19.0 and 30.0 kg/m² inclusive); for female subjects, body weight between 45.0 and 120.0 kg (45.0 kg inclusive and 120.0 kg exclusive); for male subjects, body weight between 50.0 and 120.0 kg (50.0 kg inclusive and 120.0 kg exclusive);
Subjects (including their partners) voluntarily adopt effective contraceptive measures from 1 month before screening to 6 months after the last administration of the study drug, and have no plans for childbearing, sperm donation, or egg donation within the next 6 months.

Exclusion criteria

Exclusion Criteria:

Subjects with a known allergy to Tecovirimat drugs, any excipient ingredients in this product, or subjects with an allergic diathesis (allergic to ≥ 2 types of substances);
Subjects with clinically significant abnormal electrocardiogram (ECG) findings or QTc prolongation as determined by the investigator (e.g., QTc interval ≥ 450 ms in males and ≥ 470 ms in females, with QTc interval calculated using the Fridericia formula);
Subjects with a creatinine clearance rate (Cockcroft-Gault formula) \< 90 mL/min;
Subjects with clinically significant abnormalities in physical examination, vital signs, laboratory tests, or other auxiliary examinations as determined by the investigator;
Subjects with current or past history of the following clinically significant diseases as determined by the investigator, including but not limited to diseases of the cardiovascular system, respiratory system, digestive system, urinary system, endocrine system, immune system, and nervous system (e.g., epilepsy);
Subjects with a current or history (within the past 3 months) of bacterial, fungal, or mycobacterial infection.;
Subjects with known clinically significant acute/chronic viral infections;
Subjects with a history of severe headache or migraine;
Subjects who have undergone major surgery within 6 months before drug administration, or plan to undergo surgery from the time of signing the informed consent form to 1 month after the end of the trial;
Subjects who have donated blood or had massive blood loss (> 450 mL) within 3 months before screening;
Subjects who smoked more than 5 cigarettes per day within 3 months before signing the informed consent form, or cannot refrain from using any tobacco products during the trial;
Subjects who consumed more than 14 units of alcohol per week within 3 months before signing the informed consent form (1 unit of alcohol ≈ 360 mL of beer, or 45 mL of spirits with 40% alcohol content, or 150 mL of wine), had a positive alcohol breath test (breath alcohol content > 0 mg/100 mL), or cannot abstain from alcohol during the trial;
Subjects who consumed grapefruit, grapefruit juice, chocolate, strong tea, coffee, or other beverages containing caffeine or alcohol within 72 hours before drug administration, or refuse to stop consuming the aforementioned beverages and foods during the trial;
Subjects who plan to engage in strenuous exercise during the trial, including contact sports or collision sports;
Subjects with a positive urine drug screen (for morphine, methamphetamine, ketamine, 3,4-methylenedioxymethamphetamine, or tetrahydrocannabinolic acid), or a history of drug abuse or drug use within 5 years before screening;
Subjects with a positive result in any of the following tests: hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (IgG), hepatitis C virus core antigen, human immunodeficiency virus (HIV) antibody, or treponema pallidum-specific antibody (TP-Ab);
Subjects who participated in other drug clinical trials within 3 months before screening (calculated starting from the time of the last drug administration in the previous trial);
Subjects who took any prescription drugs, over-the-counter drugs, or traditional Chinese herbal medicines within 30 days before screening;
Subjects with a positive pregnancy test result;
Subjects who cannot tolerate venipuncture, or have a history of hematophobia (fear of blood) or trypanophobia (fear of needles);
Subjects who developed an acute illness or required concomitant medication from the screening phase to before the first drug administration;
Subjects who received a vaccine within 2 weeks before screening, or plan to receive a vaccine during the trial;
Subjects deemed unsuitable for participation in this trial by the investigator.

Study design

Phase: Phase 1
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel assignment
Masking: Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment: 76 participants (estimated)

Study arms

Experimental
SAD Cohort 1
A single dose of 37.5mg BSY001 for injection or placebo administered, with 6 subjects receiving BSY001 for injection and 2 subjects receiving the placebo
Drug: BSY001 for Injection (37.5mg) · Drug: placebo-SAD
Experimental
SAD Cohort 2
A single dose of 75 mg BSY001 for injection or placebo administered, with 6 subjects receiving BSY001 for injection and 2 subjects receiving the placebo
Drug: BSY001 for Injection (75 mg) · Drug: placebo-SAD
Experimental
SAD Cohort 3
A single dose of 150 mg BSY001 for injection or placebo administered, with 8 subjects receiving BSY001 for injection and 2 subjects receiving the placebo
Drug: BSY001 for Injection (150 mg) · Drug: placebo-SAD
Experimental
SAD Cohort 4
A single dose of 200 mg BSY001 for injection or placebo administered, with 8 subjects receiving BSY001 for injection and 2 subjects receiving the placebo
Drug: BSY001 for Injection (200 mg) · Drug: placebo-SAD
Experimental
SAD Cohort 5
A single dose of 300 mg BSY001 for injection or placebo administered, with 8 subjects receiving BSY001 for injection and 2 subjects receiving the placebo
Drug: BSY001 for Injection (300 mg) · Drug: placebo-SAD
Experimental
MAD Cohort
Administer 200 mg of BSY001 or placebo every 12 hours for 14 consecutive days. Among them, 24 subjects will receive BSY001 for injection, and the other 6 subjects will receive placebo.
Drug: BSY001 for Injection · Drug: placebo-MAD

Interventions

DrugBSY001 for Injection (37.5mg)
A single dose of 37.5mg BSY001 for injection.
DrugBSY001 for Injection (75 mg)
A single dose of 75 mg BSY001 for injection.
DrugBSY001 for Injection (150 mg)
A single dose of 150 mg BSY001 for injection.
DrugBSY001 for Injection (200 mg)
A single dose of 200 mg BSY001 for injection.
DrugBSY001 for Injection (300 mg)
A single dose of 300 mg BSY001 for injection.
Drugplacebo-SAD
A single dose for injection.
DrugBSY001 for Injection
Administer 200 mg of BSY001 every 12 hours for 14 consecutive days.
Drugplacebo-MAD
Administer placebo every 12 hours for 14 consecutive days.

What researchers measure

Primary outcomes

Safety and Tolerability Parameters (SAD) - TEAE
Number and percentage of TEAE
Time frame: 10 days
Safety and Tolerability (SAD) - Lab tests
Lab tests (complete blood count, serum biochemistry, and coagulation parameters) at baseline compared to Lab tests 4 days and 10 days post dose.
Time frame: Day 4 and day 10 post dose
Safety and Tolerability (SAD) - Physical Examination
Physical Examination at Baseline Compared to Physical Examination 4,10 Days Post Dose
Time frame: Day 4 and Day 10
Safety and Tolerability Parameters (SAD) - Vital Signs
Vital signs at baseline compared to Vital signs (temperature, blood pressure, pulse, breath) day 1 pre dose, day 1, 2, 3, 4, and 10 post dose
Time frame: Day 1 pre dose; Day 1, 2, 3, 4, and 10 post dose
Safety and Tolerability (SAD) - Electrocardiogram
Electrocardiogram at Baseline Compared to Electrocardiogram day 1 pre dose, 1, 4, 10 Days Post Dose
Time frame: Day 1 pre dose, Day 1, 4, 10 post dose
Pharmacokinetics (MAD) - Cmax
Maximum observed plasma drug concentration.
Time frame: Day 1/14 (1st/2nd dose): Within 30 min pre-dose; 0.5, 1, 2, 4, 6 ,6.5, 8, 9, 10, 12 hours post-dose. Day 4, 6, 12, 13: Within 30 min before daily first dose. 24, 48, 72, 96, 120, 144 hours after the first dose on Day 14.
Pharmacokinetics (MAD) - Cmax,ss
Steady-state peak plasma concentration
Time frame: Day 1/14 (1st/2nd dose): Within 30 min pre-dose; 0.5, 1, 2, 4, 6 ,6.5, 8, 9, 10, 12 hours post-dose. Day 4, 6, 12, 13: Within 30 min before daily first dose. 24, 48, 72, 96, 120, 144 hours after the first dose on Day 14.
Pharmacokinetics (MAD) - Cmin,ss
Steady-state trough plasma concentration
Time frame: Day 1/14 (1st/2nd dose): Within 30 min pre-dose; 0.5, 1, 2, 4, 6 ,6.5, 8, 9, 10, 12 hours post-dose. Day 4, 6, 12, 13: Within 30 min before daily first dose. 24, 48, 72, 96, 120, 144 hours after the first dose on Day 14.
Pharmacokinetics (MAD) - Ctrough,ss
Steady-state trough concentration
Time frame: Day 1/14 (1st/2nd dose): Within 30 min pre-dose; 0.5, 1, 2, 4, 6 ,6.5, 8, 9, 10, 12 hours post-dose. Day 4, 6, 12, 13: Within 30 min before daily first dose. 24, 48, 72, 96, 120, 144 hours after the first dose on Day 14.
Pharmacokinetics (MAD) - Tmax
Time to peak concentration
Time frame: Day 1/14 (1st/2nd dose): Within 30 min pre-dose; 0.5, 1, 2, 4, 6 ,6.5, 8, 9, 10, 12 hours post-dose. Day 4, 6, 12, 13: Within 30 min before daily first dose. 24, 48, 72, 96, 120, 144 hours after the first dose on Day 14.
Pharmacokinetics (MAD) - Tmax,ss
Steady-state time to peak concentration
Time frame: Day 1/14 (1st/2nd dose): Within 30 min pre-dose; 0.5, 1, 2, 4, 6 ,6.5, 8, 9, 10, 12 hours post-dose. Day 4, 6, 12, 13: Within 30 min before daily first dose. 24, 48, 72, 96, 120, 144 hours after the first dose on Day 14.
Pharmacokinetics (MAD) - AUC0-t
Area under the plasma concentration-time curve from time 0 to the last measurable concentration
Time frame: Day 1/14 (1st/2nd dose): Within 30 min pre-dose; 0.5, 1, 2, 4, 6 ,6.5, 8, 9, 10, 12 hours post-dose. Day 4, 6, 12, 13: Within 30 min before daily first dose. 24, 48, 72, 96, 120, 144 hours after the first dose on Day 14.
Pharmacokinetics (MAD) - AUC0-∞
Area under the plasma concentration-time curve from time 0 extrapolated to infinity
Time frame: Day 1/14 (1st/2nd dose): Within 30 min pre-dose; 0.5, 1, 2, 4, 6 ,6.5, 8, 9, 10, 12 hours post-dose. Day 4, 6, 12, 13: Within 30 min before daily first dose. 24, 48, 72, 96, 120, 144 hours after the first dose on Day 14.
Pharmacokinetics (MAD) - AUC0-12h, AUC0-24h
Area under the plasma concentration-time curve from 0 to 12 hours and 0 to 24 hours
Time frame: Day 1/14 (1st/2nd dose): Within 30 min pre-dose; 0.5, 1, 2, 4, 6 ,6.5, 8, 9, 10, 12 hours post-dose. Day 4, 6, 12, 13: Within 30 min before daily first dose. 24, 48, 72, 96, 120, 144 hours after the first dose on Day 14.
Pharmacokinetics (MAD) - t½,z
Terminal elimination half-life
Time frame: Day 1/14 (1st/2nd dose): Within 30 min pre-dose; 0.5, 1, 2, 4, 6 ,6.5, 8, 9, 10, 12 hours post-dose. Day 4, 6, 12, 13: Within 30 min before daily first dose. 24, 48, 72, 96, 120, 144 hours after the first dose on Day 14.
Pharmacokinetics (MAD) - λz
Terminal elimination rate constant
Time frame: Day 1/14 (1st/2nd dose): Within 30 min pre-dose; 0.5, 1, 2, 4, 6 ,6.5, 8, 9, 10, 12 hours post-dose. Day 4, 6, 12, 13: Within 30 min before daily first dose. 24, 48, 72, 96, 120, 144 hours after the first dose on Day 14.
Pharmacokinetics (MAD) - CLz
Clearance
Time frame: Day 1/14 (1st/2nd dose): Within 30 min pre-dose; 0.5, 1, 2, 4, 6 ,6.5, 8, 9, 10, 12 hours post-dose. Day 4, 6, 12, 13: Within 30 min before daily first dose. 24, 48, 72, 96, 120, 144 hours after the first dose on Day 14.
Pharmacokinetics (MAD) - Vz
Apparent volume of distribution
Time frame: Day 1/14 (1st/2nd dose): Within 30 min pre-dose; 0.5, 1, 2, 4, 6 ,6.5, 8, 9, 10, 12 hours post-dose. Day 4, 6, 12, 13: Within 30 min before daily first dose. 24, 48, 72, 96, 120, 144 hours after the first dose on Day 14.
Pharmacokinetics (MAD) - RCmax
Accumulation ratio based on Cmax
Time frame: Day 1/14 (1st/2nd dose): Within 30 min pre-dose; 0.5, 1, 2, 4, 6 ,6.5, 8, 9, 10, 12 hours post-dose. Day 4, 6, 12, 13: Within 30 min before daily first dose. 24, 48, 72, 96, 120, 144 hours after the first dose on Day 14.
Pharmacokinetics (MAD) - RAUC
Accumulation ratio based on AUC
Time frame: Day 1/14 (1st/2nd dose): Within 30 min pre-dose; 0.5, 1, 2, 4, 6 ,6.5, 8, 9, 10, 12 hours post-dose. Day 4, 6, 12, 13: Within 30 min before daily first dose. 24, 48, 72, 96, 120, 144 hours after the first dose on Day 14.

Secondary outcomes

Pharmacokinetics (SAD) - Cmax
Maximum observed plasma drug concentration before administration (within 0.5 hours); and at 0.5, 1, 2, 4, 6 (immediately post-dosing), 6.5, 8, 9, 10, 12, 16, 24, 48, and 72 hours after administration.
Time frame: Before administration (within 0.5 hours); and at 0.5, 1, 2, 4, 6 (immediately post-dosing), 6.5, 8, 9, 10, 12, 16, 24, 48, and 72 hours after administration.
Pharmacokinetics (SAD) - Tmax
Time to reach Cmax before administration (within 0.5 hours); and at 0.5, 1, 2, 4, 6 (immediately post-dosing), 6.5, 8, 9, 10, 12, 16, 24, 48, and 72 hours after administration.
Time frame: Before administration (within 0.5 hours); and at 0.5, 1, 2, 4, 6 (immediately post-dosing), 6.5, 8, 9, 10, 12, 16, 24, 48, and 72 hours after administration.
Pharmacokinetics (SAD) - AUC0-t
Area under the plasma concentration vs. time curve (AUC) from time 0 to the last quantifiable measurement. Samples were collected before administration (within 0.5 hours); and at 0.5, 1, 2, 4, 6 (immediately post-dosing), 6.5, 8, 9, 10, 12, 16, 24, 48, and 72 hours after administration.
Time frame: Before administration (within 0.5 hours); and at 0.5, 1, 2, 4, 6 (immediately post-dosing), 6.5, 8, 9, 10, 12, 16, 24, 48, and 72 hours after administration.
Pharmacokinetics (SAD) - AUC0-∞
AUC from time 0 extrapolated to infinity
Time frame: Before administration (within 0.5 hours); and at 0.5, 1, 2, 4, 6 (immediately post-dosing), 6.5, 8, 9, 10, 12, 16, 24, 48, and 72 hours after administration.
Pharmacokinetics - AUC0-12h
Area under the plasma concentration vs. time curve (AUC) from time 0 to the 12-hour time-point
Time frame: Before administration (within 0.5 hours); and at 0.5, 1, 2, 4, 6 (immediately post-dosing), 6.5, 8, 9, 10, 12, 16, 24, 48, and 72 hours after administration.
Pharmacokinetics (SAD) - AUC0-24h
Area under the plasma concentration vs. time curve (AUC) from time 0 to the 24-hour time-point
Time frame: Before administration (within 0.5 hours); and at 0.5, 1, 2, 4, 6 (immediately post-dosing), 6.5, 8, 9, 10, 12, 16, 24, 48, and 72 hours after administration.
Pharmacokinetics (SAD) - t1/2 z
Terminal elimination half-life
Time frame: Before administration (within 0.5 hours); and at 0.5, 1, 2, 4, 6 (immediately post-dosing), 6.5, 8, 9, 10, 12, 16, 24, 48, and 72 hours after administration.
Pharmacokinetics (SAD) - λz
Terminal elimination rate constant
Time frame: Before administration (within 0.5 hours); and at 0.5, 1, 2, 4, 6 (immediately post-dosing), 6.5, 8, 9, 10, 12, 16, 24, 48, and 72 hours after administration.
Pharmacokinetics (SAD) - CLz
Apparent total body clearance
Time frame: Before administration (within 0.5 hours); and at 0.5, 1, 2, 4, 6 (immediately post-dosing), 6.5, 8, 9, 10, 12, 16, 24, 48, and 72 hours after administration.
Pharmacokinetics (SAD) - Vz
Apparent volume of distribution
Time frame: Before administration (within 0.5 hours); and at 0.5, 1, 2, 4, 6 (immediately post-dosing), 6.5, 8, 9, 10, 12, 16, 24, 48, and 72 hours after administration.
Safety (MAD) - TEAE
Number and percentage of TEAE
Time frame: 20 days
Safety (MAD) - Lab tests
Lab tests (complete blood count, serum biochemistry, and coagulation parameters) at baseline compared to Lab tests at day 2\~6, day 7 and day 14, day 20.
Time frame: day 2~6, day 7 and day 14, day 20.
Safety (MAD) - Physical Examination
Physical Examination at Baseline Compared to Physical Examination at day 20
Time frame: Day 20
Safety (MAD) - Electrocardiogram
Electrocardiogram at Baseline Compared to Electrocardiogram 1 day pre dose, day 1, 2\~6, 7, 14, 20.
Time frame: 1 day pre dose, day 1, 2~6, 7, 14, 20.
Safety (MAD) - Vital Signs
Vital signs at baseline compared to Vital signs (temperature, blood pressure, pulse, breath) day 1 pre dose, day 1, 2\~6, 7,8\~13, 14, and 20
Time frame: day 1 pre dose, day 1, 2~6, 7,8~13, 14, and 20

Study locations

1 of 1 sites recruiting

Shulan (Hangzhou) Hospital
Hangzhou, China
- Guiling Chen · Contact · chenguiling707@126.com · +86-18343113983
Recruiting

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

Registry details

Key details

Study ID: NCT07377175
Lead sponsor: China National Biotec Group Company Limited
Collaborators: Beijing Institute of Biological Products Co Ltd., Shulan (Hangzhou) Hospital
Responsible party: Sponsor
First posted: Jan 29, 2026
Start date: Aug 28, 2025
Primary completion: Feb 13, 2026 (estimated)
Completion: Feb 13, 2026 (estimated)
Last update: Jan 29, 2026

Study contacts

Wei Wang

Contact

nvsiclinicaltrials@163.com

+86-010-60963099

Oversight

Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Smallpox→

Other studies from this sponsor

China National Biotec Group Company Limited

Start the discussion